Previous 10 | Next 10 |
2024-04-05 09:19:01 ET More on AngioDynamics AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics gets FDA clearance for pulmonary embolism treatment device AngioDynamics Q3 2024 Ear...
2024-04-05 08:34:13 ET More on premarket gainers & stock NuScale Power Shows Too Many Red Flags NuScale Power: Attractive, Yet High-Risk Nuclear Energy Business NuScale Power Corporation (SMR) Q3 2023 Earnings Call Transcript EIGR, ADXN and BROG are among...
2024-04-05 08:00:12 ET Steven Lichtman from Oppenheimer issued a price target of $12.00 for ANGO on 2024-04-05 07:15:00. The adjusted price target was set to $12.00. At the time of the announcement, ANGO was trading at $6.4. The overall price target consensus is at $22.0...
2024-04-04 17:29:32 ET Gainers: Candel Therapeutics ( CADL ) +38% . Grindrod Shipping ( GRIN ) +28% . AngioDynamics ( ANGO ) +14% . Petco Health and Wellness Company ( WOOF ) +7% . Marinus Pharmaceuticals ( MRNS ) +5% . ...
2024-04-04 11:11:03 ET AngioDynamics Inc. (ANGO) Q3 2024 Earnings Conference Call April 4, 2024 8:00 am ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call...
2024-04-04 07:41:17 ET AngioDynamics ( NASDAQ: ANGO ) has secured a label expansion for its AlphaVac F1885 System from the U.S. Food and Drug Administration (FDA).... Read the full article on Seeking Alpha For further details see: AngioDynamics gets FDA clearance...
2024-04-04 07:04:49 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics Q3 2024 Ear...
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax...
New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical Scenarios AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expandin...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...